Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $225.4 million.

  • Cartesian Therapeutics' Non-Current Assets fell 0.34% to $225.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.4 million, marking a year-over-year decrease of 0.34%. This contributed to the annual value of $218.4 million for FY2024, which is 1.90% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Non-Current Assets stood at $225.4 million, which was down 0.04% from $225.5 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Assets registered a high of $226.2 million during Q3 2024, and its lowest value of $13.6 million during Q1 2021.
  • For the 3-year period, Cartesian Therapeutics' Non-Current Assets averaged around $165.6 million, with its median value being $218.4 million (2024).
  • Per our database at Business Quant, Cartesian Therapeutics' Non-Current Assets decreased by 13.04% in 2023 and then soared by 1,299.20% in 2024.
  • Cartesian Therapeutics' Non-Current Assets (Quarterly) stood at $15.4 million in 2021, then climbed by 14.95% to $17.7 million in 2022, then spiked by 1,107.58% to $214.3 million in 2023, then climbed by 1.90% to $218.4 million in 2024, then fell by 0.34% to $225.4 million in 2025.
  • Its last three reported values are $225.4 million in Q3 2025, $225.5 million for Q2 2025, and $224.0 million during Q1 2025.